fep blue glp 1 coverage 2025 Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know Tier exceptions no longer allowed

[90] In March 2026, the CHMP recommended granting a conditional marketing authorization for Kayshild (semaglutide), a GLP-1 receptor agonist for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, a serious disease where fat deposits accumulate in the liver causing inflammation

That matters because blood-sugar control does the opposite: HbA1c is nearly maxed out by 10 mg, so the top dose is justified by weight, not by additional glucose lowering. Body size also shifts the felt dose

Koska J, Sands M, Burciu C, D'Souza KM, Raravikar K, Liu J, Truran S, Franco DA, Schwartz EA, Schwenke DC

An obliging overachiever, it comes bearing a host of benefits